MedMira Receives Patent for its Unique Quantitative Diagnostic System
06 June 2022 - 9:48PM
Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of
a U.S. patent (number 11,353,450) for their new innovative and
quantitative test system. Through this new patent, MedMira is to
further diversify its patent portfolio and expand on its Rapid
Vertical Flow Technology® (RVF) based diagnostic tests. This is a
step forward in empowering the Company’s strategic vision by
offering a rapid multiplexed quantitative diagnostic system from
screening to confirmation to monitoring disease progression. The
synergies between both patented technologies allow MedMira to
continue its corporate aim to provide the market with a highly
effective and affordable alternative to the current costly and
time-consuming screening and monitoring systems.
“Our RVF Technology® based rapid test provides
an immediate quality Yes or No answer enabling health care
providers to diagnose specific marker(s) at a true Point-of-Care
situation. We strongly believe in the value of such affordable and
easy-to-use testing methods, which the world has clearly seen with
the COVID-19 pandemic. We are fortunate enough to expand our
offering to the market by adding value with the latest success of
our technology development – The
MIROQ™ system.
MIROQ™ allows health care providers to
receive an immediate diagnosis with both qualitative AND
quantitative results and continue disease monitoring in minutes at
the most affordable price. With the growing global population, the
increase of health issues and the overall economical adverse
situation – MedMira brings diagnostic tools that can be used
anywhere at the lowest possible cost,” said Hermes Chan, CEO of
MedMira Inc. “The synergies of both systems provide the ultimate
answer to help people know at the fastest possible time. This is
not just the next step for our corporate development, it is also a
distributive technology that outlines the much-needed shift from
the high maintenance and costly screening and diagnostic tools to
something that makes sense in today’s world.”
MedMira’s latest novel diagnostic system allows
for accessible and efficient diagnostic tools for quantitative
results in minutes. The user-friendly interface combined with
automated interpretation allows for an expansion of MedMira’s
current RVF-based tests and can provide a pathway to significantly
increase the technology’s multiplexing abilities. The combination
of the RVF and Surface-Enhanced Raman Spectroscopy* (SERS)
technology, creates MedMira’s patented novel high quality and
cost-effective tool for the next generation -
MIROQ™. This enables the amplification of the
results produced by MedMira’s RVF-based rapid tests by creating a
unique 3D structure with remarkable reproducibility that is yielded
in a linear plot (R2 = 0.98). The new addition to MedMira’s patent
family creates perfect collaboration to expand its access in both
the clinical immunoassay and the Point-of-Care markets, opening new
doors into the evolving diagnostic landscape by providing both
qualitative and quantitative test results in minutes.
The company developed the first prototype system
in 2014 and went through extensive verification and validation
performed by our academic partners here in NS, Canada. These
findings were published in the Journal of Analytical Chemistry in
November 2016 and describe the performance and efficiency of this
technology to be on par with traditional expensive laboratory
testing solutions which are generally limited to high complexity
labs. This patented system with the proprietary build-in data
capture and analysis software allows for immediate analysis of any
positive (reactive) results within 1 min. This is in contrast to
the current laboratory systems that may take from a couple of hours
and up to a week to process samples.
MedMira will provide in the coming months the
launch plan and next steps.
*Surface-enhanced Raman Spectroscopy (SERS) is a
technique that enhances Raman scattering of molecules embedded on a
given surface by several orders of magnitude through the
amplification of the electron cloud density around these molecules.
Typical SERS signal enhancement factors (EF) are observed between
106 and 1010 times, thus enabling a lower limit of detection and
making the tests more sensitive.
About MedMira
MedMira is a leading developer and manufacturer
of Rapid Vertical Flow® diagnostics. The Company’s tests provide
hospitals, labs, clinics and individuals with instant disease
diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in
just three easy steps. The Company’s tests are sold globally under
the REVEAL®, REVEALCOVID-19® , Multiplo® and Miriad® brands. Based
on its patented Rapid Vertical Flow® Technology, MedMira’s rapid
HIV test is the only one in the world to achieve regulatory
approvals in Canada, the United States, China and the European
Union. MedMira’s corporate offices and manufacturing facilities are
located in Halifax, Nova Scotia, Canada. For more information visit
medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward‐looking
statements, which involve risk and uncertainties and reflect the
Company’s current expectation regarding future events, including
statements regarding possible regulatory approval, product launch,
future growth, and new business opportunities. Actual events could
materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
MedMira ContactMarkus MeileChief
Financial Officer MedMira Inc.ir@medmira.com
MedMira (TSXV:MIR)
Historical Stock Chart
From Oct 2024 to Nov 2024
MedMira (TSXV:MIR)
Historical Stock Chart
From Nov 2023 to Nov 2024